Palvella Therapeutics (PVLA) EBIT Margin (2016 - 2024)
Historic EBIT Margin for Palvella Therapeutics (PVLA) over the last 11 years, with Q4 2024 value amounting to 2412.15%.
- Palvella Therapeutics' EBIT Margin rose 13816700.0% to 2412.15% in Q4 2024 from the same period last year, while for Dec 2024 it was 11011.72%, marking a year-over-year increase of 110393800.0%. This contributed to the annual value of 3277.91% for FY2024, which is 33056300.0% up from last year.
- According to the latest figures from Q4 2024, Palvella Therapeutics' EBIT Margin is 2412.15%, which was up 13816700.0% from 3318.87% recorded in Q1 2024.
- Over the past 5 years, Palvella Therapeutics' EBIT Margin peaked at 2412.15% during Q4 2024, and registered a low of 3318.87% during Q1 2024.
- Moreover, its 5-year median value for EBIT Margin was 163.66% (2021), whereas its average is 213.55%.
- Within the past 5 years, the most significant YoY rise in Palvella Therapeutics' EBIT Margin was 13816700bps (2024), while the steepest drop was -25471800bps (2024).
- Over the past 5 years, Palvella Therapeutics' EBIT Margin (Quarter) stood at 661.21% in 2020, then skyrocketed by 80bps to 130.27% in 2021, then tumbled by -51bps to 197.04% in 2022, then soared by 623bps to 1030.48% in 2023, then soared by 134bps to 2412.15% in 2024.
- Its last three reported values are 2412.15% in Q4 2024, 3318.87% for Q1 2024, and 1030.48% during Q4 2023.